Cardeas Pharma competitorsClear all

Cardeas Pharma's top competitors include Humanigen, Chimerix, Synthetic Biologics and Celldex Therapeutics.
Cardeas Pharma
Cardeas Pharma
Relay Therapeutics was founded on the premise that putting protein motion at the heart of drug discovery can dramatically expand therapeutic possibilities.
Humanigen
Humanigen
Humanigen is repositioning and developing its proprietary monoclonal antibodies to meet some critical unmet needs in cancer science.
Chimerix
Chimerix
Chimerix is a biopharmaceutical company discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients.
Synthetic Biologics
Synthetic Biologics
Synthetic Biologics is a late-stage clinical company developing therapeutics designed to preserve the microbiome.
Celldex Therapeutics
Celldex Therapeutics
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate.
Founding Date
Founding Date
2010
Founding Date
2000
Founding Date
2000
Founding Date
2001
Founding Date
1983
Type
Type
Private
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Cambridge, US HQ
Locations
Brisbane, US HQ
Locations
Durham, US HQ
Locations
Rockville, US HQ
Locations
Hampton, US HQ
Needham, US
Branford, US
Fall River, US
Employees
Employees
N/A
Employees
325% decrease
Employees
82
Employees
1346% decrease
Employees
13331% decrease
Valuation ($)
Valuation ($)
N/A
Valuation ($)
86.7 m
Valuation ($)
172.1 m
Valuation ($)
276.8 k
Valuation ($)
34.6 m
Twitter followers
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
900
Twitter followers
1.3 k
Twitter followers
N/A
Alexa Website Rank
Alexa Website Rank
N/A
Alexa Website Rank
904056
Alexa Website Rank
807675
Alexa Website Rank
799031
Alexa Website Rank
614281

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
$7.2m (FY, 2018)
Revenue (est.)
N/A
Revenue (est.)
$9.5m (FY, 2018)
Net income
Net income
N/A
Net income
($12m) (FY, 2018)
Net income
($69.5m) (FY, 2018)
Net income
($13.4m) (FY, 2018)
Net income
($151.2m) (FY, 2018)

Funding

Total funding raised
Total funding raised
$ 46m
Total funding raised
$ 124.2m
Total funding raised
N/A
Total funding raised
$ 16.1m
Total funding raised
$ 2m
For sources of this data, please see the company profile

View company profiles

Humanigen
HQ
Brisbane, US
Employees
3↓ 25% decrease

Humanigen is repositioning and developing its proprietary monoclonal antibodies to meet some critical unmet needs in cancer science.

View company
Chimerix
HQ
Durham, US
Employees
82

Chimerix is a biopharmaceutical company discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients.

View company
Synthetic Biologics
HQ
Rockville, US
Employees
13↓ 46% decrease

Synthetic Biologics is a late-stage clinical company developing therapeutics designed to preserve the microbiome.

View company
Celldex Therapeutics
HQ
Hampton, US
Employees
133↓ 31% decrease

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate.

View company